BioXtek is revolutionizing healthcare by turning the products of a single birth into powerful therapies that transform patient care.
At birth, the child is the headline while the rest of the equipment, which has played a crucial role in the delicate process of forming a fully functional human being from just two cells, is often discarded as medical waste. But what if these so-called "products" hold the key to medical treatment? Enter BioXtek™, a leading biotechnology specializing in regenerative medicine derived from native tissue.
BioXtek envisions a future where medical treatments, carefully created from human placental tissue and its components, can become medical treatments. These treatments aim to restore diseased or injured tissue at the cellular level, offering a revolutionary approach to healing that brings regenerative medicine into mainstream medicine, and focuses on disease eradication, not management. just the symptoms.
The company focuses on the study of amniotic fluid and Wharton’s jelly, researching cellular and acellular functions in various diseases. BioXtek’s innovative manufacturing platform aims to deliver stable, potent and sustainable exosomes at scale, creating a diverse therapeutic platform that addresses unmet needs in the treatment of injuries, musculoskeletal problems and diseases of human organs.
Longevity.Technology: BioXtek’s goal is to revolutionize allopathic medical treatment by introducing a new biological paradigm focused on achieving good results for patients without side effects or side effects. Sourced from qualified placental donors and using advanced cryopreservation and freeze-drying technology, BioXtek products focus on biologically active components such as exosomes, growth factors, peptides, cytokines, miRNA and mesenchymal stem cells. BioXtek solutions address important aspects of longevity and aging by promoting cell regeneration, reducing inflammation and preventing fibrosis.
We sat down with Dr. Bruce Werber, CEO BioXtek to learn more about the incredible regenerative potential of placental tissue and the company’s move to use this power to reverse traditional prescription drugs by addressing diseases rather than treating them there is no end.
The BioXtek platform is built around the BIOPUR process – Preserving the bioactive properties of placental tissue. Designed to ensure the preservation of the bioactive properties of placental tissue, it focuses mainly on components such as Wharton’s Jelly and amniotic fluid.
After acceptance and a strict donor screening that examines the medical history and ensures the absence of communicable diseases including COVID-19, the tissue is collected in a sterile environment immediately after childbirth; C-section delivery prefers to minimize contamination, and cellular components are removed with structural proteins and extracellular matrix intact and exosomes and other nanoparticles are preserved.
"We ensure that structural proteins such as collagen and glycosaminoglycans are preserved to maintain the integrity of the ECM, and maintain high levels of growth factors such as EGF, PDGF, and cytokines to improve the properties of the cells. it is also necessary to preserve exosomes and microRNAs that play an important role in intercellular communication and tissue repair," said Werber, adding that the team is careful to maintain low temperatures during collection and processing. first to maintain the integrity of the bioactive molecule.
Werber explained that the BIOPUR process combines advanced biotechnological techniques to ensure the highest quality and efficiency of placental tissue products. "By maintaining strict control over the entire process from supplier screening to final product certification, BIOPUR ensures the preservation of essential bioactive properties, making these products will be very effective in regenerative medicine."
Regeneration, of course, is the name of the game, and Werber explains that amniotic fluid and Wharton’s jelly are powerful biological resources that have unique regenerative properties that make them effective in creating an anti- fibrotic and anti-inflammatory which is beneficial. These abilities obviously have great therapeutic potential in a variety of medical applications.
"Amniotic fluid and Wharton’s Jelly are rich in growth factors and cytokines that play an important role in promoting cell growth, cell proliferation and differentiation," he said, adding that these molecules these help to regenerate and repair cells by improving cell communication and creating a positive environment. for healing [1].
Fat is also full of growth factors that are essential for cell proliferation and tissue repair, while cytokines, which are pro- or anti-inflammatory, help balance inflammation. and supports cell regeneration. [2].
"These biological substances have strong anti-inflammatory properties, which are essential for reducing inflammation and promoting a healing environment, and the components of the amniotic fluid and Wharton’s Jelly help prevent and reducing fibrosis, which is the reduction of connective tissue," said Werber, explaining that these substances also help to maintain cell integrity and prevent fibrosis and that extracellular vesicles and exosomes play a role important site of intercellular communication and cell regeneration.
Regeneration and wound repair slows with aging, but this can affect mobility and quality of life. Add other complications of aging, such as diabetic ulcers, and it’s clear why the products help with regeneration.
BioXtek manufactures a variety of membrane patches derived from the human placental sac in a variety of formats to ensure optimal healing and restoration in a variety of medical conditions; Each system has unique structural and functional characteristics that affect its effectiveness in different clinical settings.
"Different configurations of placental sac patches – single amnion, double amnion, tri-layer, and quad-layer – are tailored to specific clinical needs," said Werber. "Single-layer patches are suitable for small wounds, while multilayer reinforcements provide mechanical support and bioactivity for more complex and extensive healing conditions. Depending on the nature of the wound, the mechanical strength required, and the duration of the desired micromolecules of choice.
The list of bioactive molecules that improve wound healing and tissue regeneration in the BioXtek range is impressive. As well as growth factors, cytokines, exosomes and many others, there are pro-angiogenic factors that promote the formation of new blood vessels, something that is essential for ensuring the delivery of nutrients and oxygen to the healing tissue.
"These bioactive molecules work together to promote cell proliferation, reduce inflammation, promote angiogenesis, and prevent fibrosis, which makes these products very effective in regenerative medicine," said Werber.
Looking forward, Werber teases several technological advances in regenerative medicine that are expected to have a major impact on BioXtek’s product development, including biomimetic scaffolds (advanced biomaterials that mimic the natural extracellular matrix and improve the efficiency of cell regeneration) and the use of 3D printing technology to create. complex cell structure that will facilitate the development of more effective and specific treatments.
"Placental-derived tissue offers great potential for personalized regenerative medicine, and BioXtek will use advanced technology to create products tailored to each patient’s needs," said Werber. “One area of interest is CRISPR and gene editing. Advances in gene editing technologies such as CRISPR/Cas9 will allow precise modification of cells and tissues, and this could improve the therapeutic potential of placental products by editing genetic defects and the improvement of reproductive capacity.
Delivery and delivery play a major role in the BioXtek platform, and also have development plans.
"Incorporating nanotechnology into regenerative medicine will allow the development of controlled release systems that provide growth factors, cytokines and other bioactive molecules in a sustainable manner," said Werber, adding that it will improve efficiency and it’s a long-term regenerative medicine.
"In addition, we are looking at advanced hydrogel systems and injectable matrices that will provide an environment that supports cell growth and regeneration, improving the delivery and retention of therapeutic agents at the site of injury. "
Of course, AI and big data are driving every plan now and in the future; the use of AI to analyze patient data and predict the response to regenerative medicine will enable more personalized and effective treatment.
"AI can help determine the most appropriate treatment regimen based on each patient’s profile, and we are currently using AI to help review medical charts from providers," Werber said. "The integration of big data analysis will facilitate the identification of new biomarkers and therapeutic targets, accelerating the development of new innovative products."
Werber said the next 5-10 years in the space will be game-changing, spurring major developments in innovative drug technology that will impact BioXtek’s product development.
"By using innovations in biomaterials, exosome and microRNA therapy, stem cell and gene editing technologies, controlled release systems, and artificial intelligence, BioXtek can improve the efficacy, safety and practice of each regenerative medicine," he concluded. "These advances will not only improve patient outcomes but also put BioXtek at the forefront of regenerative medicine."
Learn more about BioXtek’s range of revitalizing products and the science behind them HERE.
[1] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7017504/
[2] https://brieflands.com/articles/hepatmon-123416.html
#BioXtek #Creating #stateoftheart #regenerative #therapies #human #body
